Table 1 Clinical characteristics of the patients at baseline.
Characteristic | Number of patients (%) (n = 205) |
|---|---|
Median age (range) | 54 (25–80) |
Menopausal status | |
Premenopausal | 82 (40%) |
Postmenopausal | 123 (60%) |
pT | |
1 | 103 (50.2%) |
≥ 2 | 102 (49.8%) |
pN | |
0 | 114 (55.6%) |
≥ 1 | 91 (44.4%) |
Histological type | |
No Special Type (NST) | 187 (91.3%) |
Others | 18 (8.7%) |
Estrogen receptor | |
Positive | 140 (68.3%) |
Negative | 65 (31.7%) |
Progesterone receptor | |
Positive | 115 (56%) |
Negative | 90 (44%) |
Grading | |
G1 or G2 | 20 (9.7%) |
G3 | 168 (82%) |
Unknown | 17 (8.3%) |
Ki-67 labeling index | |
< 20% | 30 (14.6%) |
≥ 20% | 169 (82.4%) |
Unknown | 6 (3%) |
HER2 | |
Positive | 78 (38%) |
Negative | 127 (62%) |
Chemotherapy regimen | |
Anthracyclines + taxanes (± trastuzumab) | 127 (62%) |
Anthracyclines | 40 (19.6%) |
Taxanes (± trastuzumab) | 19 (9.2%) |
Others | 19 (9.2%) |
